Journal article
Association between serum hepcidin-25 and primary resistance to erythropoiesis-stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial
J Gummer, R Trengove, EM Pascoe, SV Badve, A Cass, P Clarke, SP McDonald, AT Morrish, E Pedagogos, V Perkovic, D Reidlinger, A Scaria, R Walker, LA Vergara, CM Hawley, DW Johnson, JK Olynyk, P Ferrari
Nephrology | Published : 2017
DOI: 10.1111/nep.12815
Abstract
Background: Pentoxifylline has been shown to increase haemoglobin levels in patients with chronic kidney disease (CKD) and erythropoietin-stimulating agent (ESA)-hyporesponsive anaemia in the Handling Erythropoietin Resistance with Oxpentifylline multicentre double-blind, randomized controlled trial. The present sub-study evaluated the effects of pentoxifylline on the iron-regulatory hormone hepcidin in patients with ESA-hyporesponsive CKD. Methods: This sub-study included 13 patients in the pentoxifylline arm (400 mg daily) and 13 in the matched placebo arm. Hepcidin-25 was measured by ultra performance liquid chromatography/quadrupole time-of-flight mass spectrometry following isolation fr..
View full abstractGrants
Funding Acknowledgements
David Johnson has previously received consultancy fees from Sanofi-Aventis. He has also previously received consultancy fees, speakers' honoraria, research grants and travel sponsorships from Amgen, Roche and Janssen-Cilag. He was the recipient of a Roche Foundation for Anaemia Research (RoFAR) Grant, which partly funded the HERO trial, and a Queensland Government Health Research Fellowship. Carmel Hawley has previously received consultancy fees, speakers' honoraria, research grants and/or travel sponsorships from Amgen, Roche and Janssen-Cilag. Jeff Coombes has received a speakers' honorarium from Roche. Alan Cass has previously received consultancy fees, speakers' honoraria and/or research grants from Amgen, Roche, Baxter, Fresenius and Merck. Rowan Walker has previously received consultancy fees, speakers' honoraria, research grants and travel sponsorships from Amgen, Roche and Janssen-Cilag and has served on Advisory Boards for Amgen, Roche and Janssen-Cilag. Eugenie Pedagogos has previously received consultancy fees, speakers' honoraria, research grants and/or travel sponsorships from Amgen, Sanofi and Roche. All other authors have no conflict of interest to declare.